Login to Your Account



Cardio3 Biosciences Seeking $32M in European IPO Market

By Cormac Sheridan
Staff Writer

Wednesday, June 26, 2013
Cardio3 Biosciences SA is the third European biotechnology company to dip its toes in the initial public offering (IPO) waters this year. The Belgian stem cell therapy developer is seeking up to €24.7 million (US$32.5 million) in an offering on the NYSE Euronext Exchanges in Brussels and Paris.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription